Pimodivir is primarily investigated for its antiviral properties, particularly in the treatment of influenza. It functions by inhibiting the polymerase complex of the influenza virus, specifically targeting the PB2 subunit, which is crucial for viral replication. This mechanism makes it effective against both seasonal and potentially pandemic strains of influenza, including those resistant to other antiviral drugs like oseltamivir. Clinical trials have explored its use as a standalone treatment or in combination with other antivirals to enhance efficacy and reduce the risk of resistance. Its application is particularly promising for severe influenza cases and in populations at higher risk of complications, such as the elderly or immunocompromised individuals. Research continues to evaluate its broader therapeutic potential and safety profile.